HomeCompareAIU vs ABBV

AIU vs ABBV: Dividend Comparison 2026

AIU yields 327.87% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AIU wins by $48.2K in total portfolio value
10 years
AIU
AIU
● Live price
327.87%
Share price
$0.61
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$150.6K
Annual income
$244.68
Full AIU calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — AIU vs ABBV

📍 AIU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAIUABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AIU + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AIU pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AIU
Annual income on $10K today (after 15% tax)
$27,868.85/yr
After 10yr DRIP, annual income (after tax)
$207.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,848.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AIU + ABBV for your $10,000?

AIU: 50%ABBV: 50%
100% ABBV50/50100% AIU
Portfolio after 10yr
$126.5K
Annual income
$12,508.22/yr
Blended yield
9.89%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

AIU
No analyst data
Altman Z
-7.2
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AIU buys
0
ABBV buys
0
No recent congressional trades found for AIU or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAIUABBV
Forward yield327.87%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.6%
Portfolio after 10y$150.6K$102.3K
Annual income after 10y$244.68$24,771.77
Total dividends collected$81.0K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: AIU vs ABBV ($10,000, DRIP)

YearAIU PortfolioAIU Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$27,093$16,393.44$11,550$430.00+$15.5KAIU
2$49,745$20,754.90$13,472$627.96+$36.3KAIU
3$71,034$17,807.01$15,906$926.08+$55.1KAIU
4$87,889$11,882.16$19,071$1,382.55+$68.8KAIU
5$100,911$6,869.85$23,302$2,095.81+$77.6KAIU
6$111,660$3,685.85$29,150$3,237.93+$82.5KAIU
7$121,382$1,905.84$37,536$5,121.41+$83.8KAIU
8$130,847$968.12$50,079$8,338.38+$80.8KAIU
9$140,494$487.67$69,753$14,065.80+$70.7KAIU
10$150,573$244.68$102,337$24,771.77+$48.2KAIU

AIU vs ABBV: Complete Analysis 2026

AIUStock

Meta Data Limited provides tutoring services for the students of kindergarten and primary, middle, and high schools (K12) in the People's Republic of China. It offers premium tutoring services for exam preparation under the OneSmart VIP brand; young children education services, including Chinese language, mathematics, science, and computer programming under the HappyMath brand; and English tutoring services focusing on early childhood under the FasTrack English brand. The company also provides online education courses under the OneSmart Online brand to existing student base from OneSmart VIP, HappyMath, and FasTrack English. As of August 31, 2021, it operated a network of 498 learning centers across 44 cities in China. The company was formerly known as OneSmart International Education Group Limited and changed its name to Meta Data Limited in April 2022. Meta Data Limited was founded in 2007 and is headquartered in Shanghai, the People's Republic of China.

Full AIU Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this AIU vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AIU vs SCHDAIU vs JEPIAIU vs OAIU vs KOAIU vs MAINAIU vs JNJAIU vs MRKAIU vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.